Sarcopenia treatment effect through inhibition of fgf18 signaling pathway
AssigneeKnu-Industry Cooperation Foundation
InventorsYong-Hyun HAN, Dong-Hyun KIM
Life of this patent
Estimating the term…
Abstract
Provided are a method for treating a muscle weakness-related disease by using an agent that inhibits the expression of a fibroblast growth factor receptor 4 (FGFR4) gene or the activity of FGFR4 protein, and a method of characterizing a responder to a therapeutic agent for a muscle weakness-related disease and a method of treating the responder by measuring an expression level of a FGF18 protein or an mRNA thereof in a biological sample, determining a responder to the therapeutic agent when the expression level of the FGF18 protein or mRNA increases, compared with a control, and administering to the responder a pharmaceutically effective amount of the agent that treats a muscle weakness-related disease.
Claims15
-20. (canceled)
A method for treating a muscle weakness-related disease comprising administering to a subject in need thereof, a composition comprising a pharmaceutically effective amount of an agent that inhibits the expression of a fibroblast growth factor receptor 4 (FGFR4) gene or the activity of FGFR4 protein.
A method for treating a muscle weakness-related disease, comprising:
- (S1) measuring an expression level of a FGF18 protein or an mRNA of a gene encoding the protein in a biological sample isolated from a subject;
- (S2) determining that a subject having an increased expression level of the FGF18 protein or an mRNA of a gene encoding the protein, as compared to a normal control sample, is suffering from a muscle weakness-related disease;
- and
- (S3) treating the subject suffering from the muscle weakness-related disease.
Dependencies are inferred from the claim text.